Earlier this month, FDA's Oncologic Drugs Advisory Committee (ODAC) voted 10-0 in favor of approval of another CAR T cell therapy targeting CD19 -- tisagenlecleucel-T (CTL019) from Novartis AG (NYSE:NVS; SIX:NOVN). CTL019 is under Priority Review by FDA to treat pediatric and young adult relapsed or refractory B cell acute lymphoblastic leukemia (ALL). Its PDUFA date is Oct. 3
>>2
Earlier this month, FDA's Oncologic Drugs Advisory Committee (ODAC) voted 10-0 in favor of approval of another CAR T cell therapy targeting CD19 -- tisagenlecleucel-T (CTL019) from Novartis AG (NYSE:NVS; SIX:NOVN). CTL019 is under Priority Review by FDA to treat pediatric and young adult relapsed or refractory B cell acute lymphoblastic leukemia (ALL). Its PDUFA date is Oct. 3